Corporate Profile

ProKidney, a pioneer in the treatment of chronic kidney disease through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney’s lead product candidate, rilparencel (also known as REACT®), is a first-of-its-kind, patented, proprietary autologous cellular therapy being evaluated in Phase 2 and Phase 3 studies for its potential to preserve kidney function in diabetic patients at high risk of kidney failure. Rilparencel has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA.

Minimum 15 minutes delayed. Source:

News Releases

Events

SEC Filings

An amendment to the SC 13G filing

SC 13G/A

Initial filing by director officer or owner of more than ten percent

3

A statement of beneficial ownership of common stock by certain persons

SC 13G